Abpro Holdings, Inc.

Abpro Holdings, Inc. (ticker: ABP) is a clinical-stage biopharmaceutical company developing antibody-based therapeutic candidates with a primary focus on oncology indications. The company filed an S-1 registration statement with the Securities and Exchange Commission on December 23, 2024, under accession number 0001213900-24-111919, marking a formal step in its access to public capital markets. Abpro operates within the biotechnology sector, advancing an engineered-antibody pipeline directed at cancers and serious diseases with significant unmet medical need. The December 2024 S-1 reflects the company's ongoing disclosure obligations as it pursues broader investor visibility. Readers seeking complete filing history, sponsor details, and transaction data for Abpro Holdings can sign up for full access at SpacDesk.